Cargando…
Upregulation of miR-142-3p Improves Drug Sensitivity of Acute Myelogenous Leukemia through Reducing P-Glycoprotein and Repressing Autophagy by Targeting HMGB1
miR-142-3p was reported to be downregulated in acute myelogenous leukemia (AML) and acted as a novel diagnostic marker. However, the regulatory effect of miR-142-3p on drug resistance of AML cells and its underlying mechanism have not been elucidated. Here, we found that miR-142-3p was significantly...
Autores principales: | Zhang, Yuan, Liu, Yufeng, Xu, Xueju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406584/ https://www.ncbi.nlm.nih.gov/pubmed/28445844 http://dx.doi.org/10.1016/j.tranon.2017.03.003 |
Ejemplares similares
-
MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1
por: Liang, Lu, et al.
Publicado: (2020) -
Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells
por: Chen, Zhiwei, et al.
Publicado: (2021) -
Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012) -
MiR-142 inhibits the development of cervical cancer by targeting HMGB1
por: Jiang, Daqiong, et al.
Publicado: (2016) -
miR-142-3p reduces the viability of human cervical cancer cells by negatively regulating the cytoplasmic localization of HMGB1
por: Dong, Hui, et al.
Publicado: (2021)